A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 100,000 shares of ARWR stock, worth $1.87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
100,000
Previous 102,100 2.06%
Holding current value
$1.87 Million
Previous $2.65 Million 27.03%
% of portfolio
0.0%
Previous 0.01%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.36 - $29.54 $40,656 - $62,034
-2,100 Reduced 2.06%
100,000 $1.94 Million
Q2 2024

Aug 14, 2024

BUY
$21.87 - $28.24 $1.38 Million - $1.79 Million
63,300 Added 163.14%
102,100 $2.65 Million
Q1 2024

May 15, 2024

SELL
$27.21 - $39.48 $1.05 Million - $1.53 Million
-38,700 Reduced 49.94%
38,800 $1.11 Million
Q4 2023

Feb 14, 2024

SELL
$21.2 - $31.03 $1.39 Million - $2.03 Million
-65,400 Reduced 45.77%
77,500 $2.37 Million
Q3 2023

Nov 14, 2023

BUY
$26.2 - $36.08 $2.38 Million - $3.28 Million
91,000 Added 175.34%
142,900 $3.84 Million
Q2 2023

Aug 14, 2023

BUY
$25.16 - $41.38 $500,684 - $823,462
19,900 Added 62.19%
51,900 $1.85 Million
Q1 2023

May 15, 2023

BUY
$23.68 - $38.51 $757,760 - $1.23 Million
32,000 New
32,000 $812,000
Q4 2021

Feb 14, 2022

SELL
$58.09 - $82.51 $1.18 Million - $1.67 Million
-20,300 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$58.38 - $84.96 $1.96 Million - $2.85 Million
-33,500 Reduced 62.27%
20,300 $1.27 Million
Q2 2021

Aug 16, 2021

SELL
$62.15 - $90.32 $2.86 Million - $4.15 Million
-46,000 Reduced 46.09%
53,800 $4.46 Million
Q1 2021

May 17, 2021

BUY
$61.35 - $90.47 $2.8 Million - $4.13 Million
45,600 Added 84.13%
99,800 $6.62 Million
Q4 2020

Feb 16, 2021

SELL
$43.82 - $85.37 $6.18 Million - $12 Million
-141,100 Reduced 72.25%
54,200 $4.16 Million
Q3 2020

Nov 16, 2020

SELL
$33.21 - $51.27 $15.5 Million - $24 Million
-467,800 Reduced 70.55%
195,300 $8.41 Million
Q2 2020

Aug 14, 2020

BUY
$26.12 - $43.27 $982,112 - $1.63 Million
37,600 Added 6.01%
663,100 $28.6 Million
Q1 2020

May 15, 2020

BUY
$20.56 - $63.12 $9.69 Million - $29.7 Million
471,300 Added 305.64%
625,500 $18 Million
Q4 2019

Feb 14, 2020

BUY
$28.14 - $73.01 $1.41 Million - $3.67 Million
50,200 Added 48.27%
154,200 $9.78 Million
Q3 2019

Nov 14, 2019

SELL
$26.26 - $34.86 $3.63 Million - $4.82 Million
-138,400 Reduced 57.1%
104,000 $2.93 Million
Q2 2019

Aug 14, 2019

BUY
$17.43 - $28.82 $2.92 Million - $4.83 Million
167,700 Added 224.5%
242,400 $6.42 Million
Q1 2019

May 15, 2019

BUY
$12.05 - $20.18 $900,135 - $1.51 Million
74,700 New
74,700 $1.37 Million
Q4 2018

Feb 14, 2019

SELL
$10.74 - $19.7 $214,800 - $394,000
-20,000 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$14.0 - $20.3 $280,000 - $406,000
20,000 New
20,000 $383,000

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $1.98B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.